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Abstract 
The prevalence of HIV in West Africa is lower than elsewhere in Africa but Gabon has one of the highest rates of HIV in that 
region. Gabon has a small population and a high per capita gross domestic product making it an ideal place to carry out a 
programme of early treatment for HIV. The effectiveness, availability and affordability of triple combination therapy make it 
possible to contemplate ending AIDS deaths and HIV transmission in the short term and HIV prevalence in the long term. Here 
we consider what would have happened in Gabon without the development of potent anti-retroviral therapy (ART), the impact 
that the current roll-out of ART has had on HIV, and what might be possible if early treatment with ART becomes available to 
all.  
 We fit a dynamic transmission model to trends in the adult prevalence of HIV and infer trends in incidence, mortality 
and the impact of ART. The availability of ART has reduced the prevalence of HIV among adults not on ART from 4.2% to 
2.9%, annual incidence from 0.43% to 0.27%, and the proportion of adults dying from AIDS illnesses each year from 0.36% to 
0.13% saving the lives of 2.3 thousand people in 2013 alone. The provision of ART has been highly cost effective saving the 
country at least $18 million up to 2013. 
 
Introduction 
The prevalence of HIV infection in Gabon has increased 
rapidly to a peak in the year 2000 and has fallen slightly 
since then. Gabon now has a reasonable proportion of 
people on ART and this has undoubtedly saved many lives 
and significantly reduced transmission. If the Gabonese 
Government follows the current recommendations of the 
World Health Organization (WHO), the International 
AIDS Society (IAS) and the Department of Health and 
Human Services (DHHS) this has the potential to end the 
epidemic. If this is to be done it will be important to 
estimate the impact that this will have on the epidemic and 
how much it will cost. Here we use UNAIDS estimates of 
the trend in the prevalence of HIV and the number of 
people currently receiving ART in Gabon. We fit these 
data to a dynamical model to estimate current, and to 
project future, trends in prevalence, incidence, treatment 
needs and deaths. We estimate the cost of HIV/AIDS to 
the country including the cost of providing drugs and 
providing support to people on ART, the cost of 
hospitalization and access to primary health care facilities. 
We do not include the cost to the county of deaths among 
young adults so that these calculations are likely to be 
conservative with respect to costs. 
Data 
The model is fitted to data provided by UNAIDS on the 
trend in the prevalence of HIV. Costs are based on a recent 
study for South Africa including the cost of 
hospitalization, primary health care and treatment.1 Data in 
this regard for Gabon would provide better estimates. The 
costs are given in Table 1. All costs are in 2013 US$ 
discounted at 3% per year. 
Model 
The model is a standard dynamical model discussed in 
detail elsewhere.4,5 In brief, the model includes uninfected 
people who are susceptible to infection while infected 
people go through four stages of infection to death as this 
gives an accurate match to the known Weibull survival for 
people infected with HIV but not ART.6 To account for 
heterogeneity in the risk of infection the transmission 
parameter declines exponentially with the prevalence of 
HIV.4,5  
Table 1. Cost of days in hospital, primary health care 
visits and counselling and testing from Granich et al.1 
Drug costs are current prices for first line drugs in 
South Africa.3 The cost of care and support covers 
community based care, the cost of a death is set to the 
GNI for Gabon.2,3 Costs are for the year 2013; future 
costs are discounted at 3.5% per year. 
Item Cost ($ p.a.) 
Inpatient days  not on ART  568 
Inpatient days  on ART  138 
Primary health care visits not on ART   154 
Primary health care visits  on ART   269 
Counselling and testing per test  11 
Cost of the death of a young adult  8,000 
Drug costs  100 
Community support and care  150 
 
Fitting the model 
We first fit the model to the prevalence data without 
including ART to get a null model against which to 
compare the impact of ART. We vary the prevalence of 
infection in 1980, which determines the timing of the 
epidemic, the rate of increase and the rate at which the risk 
of infection declines as the prevalence increases as this 
determines the peak value of the prevalence. This gives the 
parameter values in Table 2.  
 To model the current level of ART provision we 
assume that certain proportions of people in the fourth 
stages of HIV infection are started on ART. We assume 
that coverage increases logistically and vary the rate and 
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timing of the increase and the proportion of people starting 
treatment in each stage to match the reported coverage of 
ART. To explore the impact of active case finding we 
again assume that coverage increases logistically at a 
realistic rate, timing and asymptotic coverage. We assume 
that all those that are found to be HIV-positive, in any 
stage of infection, are eligible for treatment. The parameter 
values are given in Table 3. 
 
Table 2. The best fit parameter values for the prevalence of 
HIV. The birth and transition rates are fixed; the other 
parameters are varied to optimize the fit. 
Parameter Value 
Birth rate/yr 0.029 
Background mortality/yr 0.018 
Force of infection/yr 0.375 
Prevalence at which transmission is halved 0.034 
Transition rate/yr between states off ART 0.348 
Transition rate/yr between ART states on ART 0.087 
 
Table 3. The model parameters are for logistic functions 
that determine coverage and testing rates. Coverage 
gives the asymptotic value, rate is the exponential rate of 
increase, ‘half-max’ gives the year when coverage 
reaches half the maximum value. Passive case finding 
applies to those that present in late stages of HIV. Active 
case finding applies to all infected people. 
 Parameter Value 
Reduction  0.38 
Rate per annum  0.93 Behaviour change 
Half-max. (year)  2002.06 
Coverage 0.50 
Rate per annum 0.90 Passive case Finding: Stage 4 
Half-max. (year) 2004.70 
Coverage 0.90 
Rate per annum 2.00 
Half-max. (year) 2014.0 
Active case 
finding: testing 
Test interval (yrs) 1.00 
Coverage 0.90 
Rate per annum 2.00 Active case finding: take-up 
Half-max. (year) 2014.00 
Results 
The fitted values of the parameters are given in Table 2 
and Table 3 and the fitted data and implied trends are 
shown in Figure 1. The graphs in Figure 1 give, from left 
to right, the prevalence of infection, the annual incidence 
of infection, of treatment and the mortality, and the costs, 
and from top to bottom the counterfactual that would have 
happened without ART, the impact of the current level of 
ART, and the predicted impact of universal access to early 
treatment.  
Without ART 
Figure 1A gives the prevalence, Figure 1B the implied 
incidence (red line) and mortality (black line) and Figure 
1C the implied costs of letting people die without ART 
(blue line) and the cost of in- and out-patient care1 (black 
line). The prevalence rises rapidly to a steady state, falls 
slightly, and then remains fairly constant after 2002 
(Figure 1A). In order to fit the drop in the observed 
prevalence we have to assume a degree of behaviour 
change leading to a 38% decline in risk, as indicated in 
Table 3. The incidence peaks, declines as people reduce 
their risky behaviour and then levels off.  The mortality 
rises about ten years after the incidence reflecting the 
mean life-expectancy of people with HIV (Figure 1B).  
 Without ART about 0.4 % of adults, or about 50k 
people, would have died in the years up to 2103 from 
AIDS and AIDS related illnesses (Figure 2B). The annual 
cost to society of providing clinical care and support for 
people with AIDS related illnesses would have peaked at 
$12 per adult in 2006, have fallen to about $9 per adult in 
2021 (Figure 1C) and then continued to rise because of the 
discounting rate for future costs. The cumulative cost of 
care and support for those infected with HIV would have 
reached US$191M in 2013 and US$355M by 2023. 
Progress so far 
The provision of ART on a significant scale in the public 
sector in South Africa expanded rapidly. Allowing for the 
provision of ART, Figure 1D gives the prevalence of those 
not on ART (red line), on ART (green line) and the total 
(blue line); Figure 1E gives the incidence of HIV (red 
line), the rate at which people start ART (green line), the 
mortality of those on ART (black line) and of those not on 
ART (grey line). Figure 1F gives the mortality of people 
not on ART (red line), on ART (green line) and all deaths 
(blue line). In Figure 1F the black line includes the cost of 
in- and out-patient care.1  Currently, about one-quarter of 
all HIV positive adults are currently believed to be on 
ART. While about 4.2% of adults are currently infected 
with HIV (Figure 1D: blue line), the prevalence among 
adults not on ART (Figure 1D red line) has fallen to about 
2.9% of adults with the remaining 1.3% on ART and if the 
current policy were to continue the prevalence in adults 
infected with HIV but not on treatment would fall to about 
2%. 
 As expected there has been a similarly large impact on 
incidence which has fallen from a peak of 0.6% per annum 
to 0.3% per annum (Figure 1E: red line) with the rate at 
which people start ART peaking at 0.4% per annum in 
2007 (Figure 1E: green line) but falling rapidly after that. 
AIDS related deaths among adults peaked in 2006 at about 
0.3% per annum but by 2013 has fallen to 0.1% per annum 
(Figure 1E: black line). Without ART about 3.2 thousand 
people would have died in 2013; the provision of ART has 
reduced this to 2.1 thousand saving more then one 
thousand lives in 2013 alone. People will, of course, 
continue to die on ART (Figure 1E: grey line) but from 
natural causes other than HIV. 
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Figure 1. Top: baseline scenario without ART. Middle: current level of treatment. Bottom: early treatment (see text for details). Left: HIV 
prevalence: Blue: Data (with 95% confidence limits) and fitted line. Red: not on ART. Green: Data for those on ART and fitted line. Middle: 
HIV incidence. Red: Incidence of HIV. Green: incidence of treatment. Black: mortality not on ART. Grey: mortality on ART. Right: Cost of 
deaths: Red cost of letting people die without ART. Green cost of keeping people alive on ART. Blue: red plus green. Black: blue plus the 
cost of in-patient and out-patient care on and off ART1 (see text for details). Brown: black plus the cost of testing.  
 While the current ART provision has saved many lives 
and greatly reduced incidence, there has also been a 
substantial cost saving; the annual cost to society has fallen 
from $50 per adult to $23 per adult (Figure 1F: black line) 
for a net cost saving of about $24M in the year 2013 alone 
and, even under the current policy of ART provision, costs 
will continue to fall. 
 Of the total cost in 2013 43% is the cost to society of 
people dying of AIDS related conditions (Figure 1F: red 
line), 14% is the cost of providing ART (Figure 1F: green 
line), and the remaining 43% is the cost of medical care 
(Figure 1F: black line).  
Universal Access to Early Treatment 
The substantial impact of treatment on the incidence, 
prevalence and mortality due to AIDS and the very 
substantial savings that accrue, encourages one to consider 
the impact of making ART available to everyone, 
regardless of CD4+ cell counts. If the Gabonese 
government chooses to adopt the 2013 guidelines of the 
World Health Organization7 about 90% of all HIV-positive 
people will be eligible for treatment as soon as they are 
found to be HIV-positive. The guidelines of the 
International AIDS Society8 and the Department of Health 
and Human Services (DHHS)9 both recommend treatment 
for those infected with HIV without regard to their CD4+ 
cell count on the grounds that this is in the best interests of 
the individual concerned and has the added benefit of 
reducing the likelihood that they will not infect their 
partners. 
 We therefore consider what would happen under a 
policy of universal access in which 90% of all adults, not 
on ART, are tested each year and 90% of those that test 
positive are started on ART, with coverage and testing 
reaching half the target levels by the end of 2014. 
 Universal access to early treatment should eliminate 
HIV transmission (Figure 1G and H: red line) and end 
AIDS related deaths by 2022 (Figure 1H: black line) but 
there would still be a very large number of HIV positive 
people on ART (Figure 1G: blue line) who would have to 
be maintained on treatment for the rest of their lives. The 
rate at which people would be started on treatment will 
have to increase to about five times the present rate (Figure 
1H: green line) in 2015 but after that would fall rapidly as 
transmission and the generation of new cases fell. Between 
2015 and 2020 the cost would be only marginally greater 
than continuing the present policy (Figure 1F: black line c.f. 
Figure 1I: black and brown lines). After 2020 there would 
be further cost savings. 
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Figure 2. A: Total cost of ART and deaths discounted at 3.5% p.a. 
B: Annual adult AIDS deaths per capita. C: Cost per death 
averted. Blue line: null hypothesis if ART had not been made 
available; Red line: assuming current level of ART provision 
continued as in Figure 1D; Green line: early treatment as 
described in the text. 
 In Figure 2 we make a direct comparison of what would 
have happened without ART, what has happened as a result 
of the roll-out of ART, and what could happen under 
universal access and early treatment following the new 
WHO,7 IAS8 and DHHS9 guidelines. The current policy has 
saved, and will continue to save, both money (Figure 2A) 
and lives (Figure 2B) in a cost effective manner (Figure 
2C). Universal access to early treatment will cost 
marginally more between 2013 and 2015 but will cost less 
after that, will save many more lives and will lead to the 
elimination of HIV and the end of AIDS related deaths at a 
cost of less than $10 thousand per death averted and falling 
sharply as the epidemic is eliminated. 
 It is important to note that by 2020 testing costs alone 
would exceed all other costs (Figure 1I). It will be 
important to find more cost-effective ways of finding 
people who are HIV-positive either through expanded 
provider initiated counselling and testing or through contact 
tracing. 
Discussion 
Gabon has been quite successful in the extent to which it 
has made ART therapy available in the public sector. 
Currently, an estimated 12 thousand people are being kept 
alive on ART with significant cost savings to the economy 
have been considerable. Expanding access will save more 
lives, will save more money and will lead to the elimination 
of HIV. 
 Although universal access to early treatment is the only 
way in which HV can be eliminated, other methods of 
support and control will play an important role.3 The two 
most critical issues are drug supply and compliance. A 
regular and reliable supply of drugs must be assured. Stock-
outs will create anger and mistrust among infected people 
and poor compliance, for any reason, will lead to viral 
rebound, treatment failure, ongoing transmission and drug 
resistance. These two considerations must be at the 
forefront of plans to effectively control and eventually 
eliminate HIV. 
 To ensure high levels of compliance it will be necessary 
to deal with problems of stigma and discrimination and to 
ensure that there is strong community involvement and 
support for people living with HIV. Adult medical male 
circumcision will significantly reduce the prevalence of 
HIV among young men and have a secondary benefit for 
young women who are the group at greatest risk. Pre-
exposure prophylaxis will provide additional protection for 
those that are unable to protect themselves as is often the 
case for women who believe that their partners may be 
infected but are unable to negotiate condom use. Condoms 
are highly effective if used properly and should be readily 
available to all that need them. Better control of other 
sexually transmitted infections is important in itself and 
will contribute further to the control of HIV. And while 
these interventions can make an important contribution to 
stopping the epidemic of HIV, universal access to early 
treatment provides an ideal entry point for each of these 
interventions. Finally, by developing programmes that are 
firmly based in local communities it will be possible to 
provide training and education as well as jobs for 
community outreach workers thereby creating jobs and 
stimulating local economies. 
 It remains important to validate these assumptions, to 
ensure the validity or otherwise of these results and to 
improve the model predictions. To do this it is imperative 
that at the next ante-natal clinic survey, in October 2013, all 
women who test positive for HIV should also be tested for 
the presence of anti-retroviral drugs, their viral loads should 
be measured and an incidence assay should be used to 
estimate incidence, 
 What will be needed is a big push, hopefully when the 
Department of Health adopts the new WHO guidelines. 
Since an estimated 90% of all HIV positive people will then 
be eligible for immediate treatment it would be advisable to 
abandon the use of CD4+ cell counts but to make viral load 
testing more widely available as a way of assessing the 
impact of the programme and of monitoring compliance. 
This analysis suggests that the rate at which people are 
currently being started on ART will have to increase by 
about four times, but only for about two years. While this 
will require considerable organization and a significant 
investment, the cost to the economy as a whole will be only 
marginally more than the cost of maintaining the present 
level of ART provision and within a few years the savings 
in both lives and money will be substantial. 
 We have the wherewithal to stop the epidemic all that is 
needed is the commitment to achieve an AIDS Free 
Generation. 
References 
1. Granich R, Kahn JG, Bennett R, et al. Expanding ART for 
Treatment and Prevention of HIV in South Africa: Estimated 
Cost and Cost-Effectiveness 2011-2050. PLOS One 2012; 7: 
e30216. 
2. Williams BG, Gouws E. Affordability, cost and cost-
effectiveness of universal anti-retroviral therapy for HIV. 
arXiv, 2012. http://arxiv.org/abs/1206.6774  
3. Williams BG. Combination prevention for the elimination of 
HIV. arXiv, 2013. Avaliable at http://arxiv.org/abs/1307.6045  
4. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. 
Universal voluntary HIV testing with immediate 
antiretroviral therapy as a strategy for elimination of HIV 
transmission: a mathematical model. Lancet 2008; 373: 48-
57. 
5. Williams BG, Granich R, De Cock K, Glaziou P, Sharma A, 
Dye C. Anti-retroviral therapy for the control of HIV-
associated tuberculosis: modelling the potential effects in 
A                                                     B 
 
 
 
 
 
C                                                     D 
 5 
nine African countries. Proceedings of the National Academy 
of Sciences 2010; 107: 17853-4. 
6. CASCADE Collaboration. Time from HIV-1 seroconversion 
to AIDS and death before widespread use of highly-active 
anti-retroviral therapy. A collaborative analysis. Lancet 2000; 
355: 1131-7. 
7. WHO. Consolidated guidelines on the use of antiretroviral 
drugs for treating and preventing HIV infection: 
Recommendations for a public health approach. Geneva: 
World Health Organization, 2013. 
http://www.who.int/hiv/pub/guidelines/arv2013/en/. 
8. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral 
therapy in adults: updated recommendations of the 
International AIDS Society-USA Panel. Journal of the 
American Medical Association 2000; 283: 381-90. 
9. DHHS. Panel on Antiretroviral Guidelines for Adults and 
Adolescents. Guidelines for the use of antiretroviral agents in 
HIV-1-infected adults and adolescents: Department of Health 
and Human Services, USA, 2013. 
http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.
pdf. 
 
 
